1. Home
  2. TBPH vs CAC Comparison

TBPH vs CAC Comparison

Compare TBPH & CAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • CAC
  • Stock Information
  • Founded
  • TBPH 2013
  • CAC 1875
  • Country
  • TBPH United States
  • CAC United States
  • Employees
  • TBPH N/A
  • CAC N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • CAC Major Banks
  • Sector
  • TBPH Health Care
  • CAC Finance
  • Exchange
  • TBPH Nasdaq
  • CAC Nasdaq
  • Market Cap
  • TBPH 699.0M
  • CAC 680.5M
  • IPO Year
  • TBPH N/A
  • CAC 1997
  • Fundamental
  • Price
  • TBPH $14.26
  • CAC $35.65
  • Analyst Decision
  • TBPH Strong Buy
  • CAC Buy
  • Analyst Count
  • TBPH 4
  • CAC 3
  • Target Price
  • TBPH $23.00
  • CAC $48.00
  • AVG Volume (30 Days)
  • TBPH 301.7K
  • CAC 77.6K
  • Earning Date
  • TBPH 11-11-2025
  • CAC 10-28-2025
  • Dividend Yield
  • TBPH N/A
  • CAC 4.71%
  • EPS Growth
  • TBPH N/A
  • CAC 4.80
  • EPS
  • TBPH 0.26
  • CAC 3.11
  • Revenue
  • TBPH $77,205,000.00
  • CAC $197,501,000.00
  • Revenue This Year
  • TBPH $79.82
  • CAC $42.11
  • Revenue Next Year
  • TBPH N/A
  • CAC $5.51
  • P/E Ratio
  • TBPH $54.87
  • CAC $11.45
  • Revenue Growth
  • TBPH 24.49
  • CAC 21.74
  • 52 Week Low
  • TBPH $7.90
  • CAC $34.53
  • 52 Week High
  • TBPH $15.15
  • CAC $50.07
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 54.96
  • CAC 34.70
  • Support Level
  • TBPH $13.50
  • CAC $35.00
  • Resistance Level
  • TBPH $14.59
  • CAC $38.38
  • Average True Range (ATR)
  • TBPH 0.50
  • CAC 1.10
  • MACD
  • TBPH -0.09
  • CAC -0.27
  • Stochastic Oscillator
  • TBPH 46.31
  • CAC 13.45

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

Share on Social Networks: